10:15AM 11/13/2014 – 10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston
Reporter: Aviva Lev-Ari, PhD, RN
REAL TIME Coverage of this Conference by Dr. Aviva Lev-Ari, PhD, RN – Director and Founder of LEADERS in PHARMACEUTICAL BUSINESS INTELLIGENCE, Boston http://pharmaceuticalintelligence.com
10:15 a.m. Panel Discussion — IT/Big Data
IT/Big Data
The human genome is composed of 6 billion nucleotides (using the genetic alphabet of T, C, G and A). As the cost of sequencing the human genome is decreasing at a rapid rate, it might not be too far into the future that every human being will be sequenced at least once in their lifetime. The sequence data together with the clinical data are going to be used more and more frequently to make clinical decisions. If that is true, we need to have secure methods of storing, retrieving and analyzing all of these data. Some people argue that this is a tsunami of data that we are not ready to handle. The panel will discuss the types and volumes of data that are being generated and how to deal with it.
Moderator:
Amy Abernethy, M.D.
Chief Medical Officer, Flatiron
Role of Informatics, SW and HW in PM. Big data and Healthcare
How Lab and Clinics can be connected. Oncologist, Hematologist use labs in clinical setting, Role of IT and Technology in the environment of the Clinicians
Compare Stanford Medical Center and Harvard Medical Center and Duke Medical Center — THREE different models in Healthcare data management
Create novel solutions: Capture the voice of the patient for integration of component: Volume, Veracity, Value
Decisions need to be made in short time frame, documentation added after the fact
No system can be perfect in all aspects
Understanding clinical record for conversion into data bases – keeping quality of data collected
Key Topics
Panelists:
Stephen Eck, M.D., Ph.D.
Vice President, Global Head of Oncology Medical Sciences,
Astellas, Inc.
Small data expert, great advantage to small data. Populations data allows for longitudinal studies,
Big Mac Big Data – Big is Good — Is data been collected suitable for what is it used, is it robust, limitations, of what the data analysis mean
Data analysis in Chemical Libraries – now annotated
Diversity data in NOTED by MDs, nuances are very great, Using Medical Records for building Billing Systems
Cases when the data needed is not known or not available — use data that is available — limits the scope of what Valuable solution can be arrived at
In Clinical Trial: needs of researchers, billing clinicians — in one system
Translation of data on disease to data object
Signal to Noise Problem — Thus Big data provided validity and power
J. Michael Gaziano, M.D., M.P.H., F.R.C.P.
Scientific Director, Massachusetts Veterans Epidemiology Research
and Information Center (MAVERIC), VA Boston Healthcare System;
Chief Division of Aging, Brigham and Women’s Hospital;
Professor of Medicine, Harvard Medical School
at BWH since 1987 at 75% – push forward the Genomics Agenda, VA system 25% – VA is horizontally data integrated embed research and knowledge — baseline questionnaire 200,000 phenotypes – questionnaire and Genomics data to be integrated, Data hierarchical way to be curated, Simple phenotypes, validate phenotypes, Probability to have susceptibility for actual disease, Genomics Medicine will benefit Clinicians
Data must be of visible quality, collect data via Telephone VA – on Med compliance study, on Ability to tolerate medication
–>>Annotation assisted in building a tool for Neurologist on Alzheimer’s Disease (AlzSWAN knowledge base) (see also Genotator , a Disease-Agnostic Tool for Annotation)
–>>Curation of data is very different than statistical analysis of Clinical Trial Data
–>>Integration of data at VA and at BWH are tow different models of SUCCESSFUL data integration models, accessing the data is also using a different model
–>>Data extraction from the Big data — an issue
–>>Where the answers are in the data, build algorithms that will pick up causes of disease: Alzheimer’s – very difficult to do
–>>system around all stakeholders: investment in connectivity, moving data, individual silo, HR, FIN, Clinical Research
–>>Biobank data and data quality
Krishna Yeshwant, M.D.
General Partner, Google Ventures;
Physician, Brigham and Women’s Hospital
Computer Scientist and Medical Student. Were the technology is going?
Messy situation, interaction IT and HC, Boston and Silicon Valley are focusing on Consumers, Google Engineers interested in developing Medical and HC applications — HUGE interest. Application or Wearable – new companies in this space, from Computer Science world to Medicine – Enterprise level – EMR or Consumer level – Wearable — both areas are very active in Silicon Valley
IT stuff in the hospital HARDER that IT in any other environment, great progress in last 5 years, security of data, privacy. Sequencing data cost of big data management with highest security
Constrained data vs non-constrained data
Opportunities for Government cooperation as a Lead needed for standardization of data objects
Questions from the Podium:
- Where is the Truth: do we have all the tools or we don’t for Genomic data usage
- Question on Interoperability
- Big Valuable data — vs Big data
- quality, uniform, large cohort, comprehensive Cancer Centers
- Volume of data can compensate quality of data
- Data from Imaging – Quality and interpretation – THREE radiologist will read cancer screening
– See more at: http://personalizedmedicine.partners.org/Education/Personalized-Medicine-Conference/Program.aspx#sthash.qGbGZXXf.dpuf
Leave a Reply